TY - JOUR
T1 - Follicle-stimulating hormone and estradiol levels in Japanese Women treated with toremifene and anastrozole for two years-A retrospective analysis of data from a prospective randomized trial
AU - Anan, Keisei
AU - Mitsuyama, Shoshu
AU - Yanagita, Yasuhiro
AU - Kimura, Morihiko
AU - Doihara, Hiroyoshi
AU - Komaki, Kansei
AU - Kusama, Mikihiro
AU - Ikeda, Tadashi
N1 - Publisher Copyright:
© 2018 Japanese Journal of Cancer and Chemotherapy Publishers Inc. All rights reserved.
PY - 2018/12
Y1 - 2018/12
N2 - The criteria for biological postmenopause have not been clearly defined, although determining the menopausal status is crucial for selecting agents for adjuvant endocrine therapy for patients with breast cancer. The long-term effects of adjuvant toremifene (TOR) and anastrozole (ANA) on serum follicle-stimulating hormone (FSH) and estradiol (E2) levels in Japanese women were examined using data from a prospective randomized study that mainly studied serum lipids and bone metabolism for 2 years. The study medications were administered orally daily at 40 mg and 1 mg for TOR and ANA, respectively. Sixty-nine patients were randomly assigned to the TOR group (n=36) or ANA group (n=33). FSH and E2 levels were measured using chemiluminescent immunoassay. The mean ages of the patients in the TOR and ANA groups were 62.5 and 60.0 years, respectively. None of the patients experienced menstruation during the course of the study. The baseline serum FSH level in the TOR group (69.6mlU/mL) decreased to 59.2%, 54.6%, and 50.0% at 6, 12, and 24 months, respectively, after therapy commencement. The FSH levels ranged from 8.6 to 68.1 mIU/mL and were<20 mIU/mL in 2 patients (9.5%; 8.6 and 14.4 mIU/mL). The serum FSH levels in the ANA group did not change markedly over 24 months. The baseline serum E2 level in the ANA group (11.6 pg/mL) decreased to 72.4%, 70.7%, and 61.2% at 6, 12, and 24months, respectively, after therapy commencement. The serum E2 level in the TOR group did not change markedly over 24 months. When switching to other endocrine agents as adjuvant therapy for patients with breast cancer treated with TOR, the serum FSH level decreased to half of the preinitiation level, and one-tenth of the FSH levels was<20 mIU/mL, while the postmenopausal serum E2 level was maintained.
AB - The criteria for biological postmenopause have not been clearly defined, although determining the menopausal status is crucial for selecting agents for adjuvant endocrine therapy for patients with breast cancer. The long-term effects of adjuvant toremifene (TOR) and anastrozole (ANA) on serum follicle-stimulating hormone (FSH) and estradiol (E2) levels in Japanese women were examined using data from a prospective randomized study that mainly studied serum lipids and bone metabolism for 2 years. The study medications were administered orally daily at 40 mg and 1 mg for TOR and ANA, respectively. Sixty-nine patients were randomly assigned to the TOR group (n=36) or ANA group (n=33). FSH and E2 levels were measured using chemiluminescent immunoassay. The mean ages of the patients in the TOR and ANA groups were 62.5 and 60.0 years, respectively. None of the patients experienced menstruation during the course of the study. The baseline serum FSH level in the TOR group (69.6mlU/mL) decreased to 59.2%, 54.6%, and 50.0% at 6, 12, and 24 months, respectively, after therapy commencement. The FSH levels ranged from 8.6 to 68.1 mIU/mL and were<20 mIU/mL in 2 patients (9.5%; 8.6 and 14.4 mIU/mL). The serum FSH levels in the ANA group did not change markedly over 24 months. The baseline serum E2 level in the ANA group (11.6 pg/mL) decreased to 72.4%, 70.7%, and 61.2% at 6, 12, and 24months, respectively, after therapy commencement. The serum E2 level in the TOR group did not change markedly over 24 months. When switching to other endocrine agents as adjuvant therapy for patients with breast cancer treated with TOR, the serum FSH level decreased to half of the preinitiation level, and one-tenth of the FSH levels was<20 mIU/mL, while the postmenopausal serum E2 level was maintained.
KW - Menopause
KW - Selective estrogen receptor modulator
UR - http://www.scopus.com/inward/record.url?scp=85059240967&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059240967&partnerID=8YFLogxK
M3 - Article
C2 - 30587728
AN - SCOPUS:85059240967
VL - 45
SP - 1725
EP - 1728
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
SN - 0385-0684
IS - 12
ER -